Chosa Oncology AB (XSAT:CHOSA) Research & Development: kr0.00 Mil (TTM As of Mar. 2026)


XSAT:CHOSA Chosa Oncology AB XSAT:CHOSA
31 GF Score
Price kr0.83
View Full Analysis

What is Chosa Oncology AB Research & Development?

Chosa Oncology AB XSAT:CHOSA 31 Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus rates XSAT:CHOSA with a GF Score™ of 31/100.

Research & Development is the aggregate amount of research and development expenses during the year. Chosa Oncology AB's Research & Development for the three months ended in Mar. 2026 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Chosa Oncology AB  (XSAT:CHOSA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Chosa Oncology AB Research & Development Related Terms

Chosa Oncology AB Research & Development Historical Data

* Premium members only.

The historical data trend for Chosa Oncology AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chosa Oncology AB Research & Development Chart

Chosa Oncology AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Chosa Oncology AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSAT:CHOSA
31GF Score
Chosa Oncology AB XSAT:CHOSA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chosa Oncology AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.00 Mil mean?
Chosa Oncology AB (XSAT:CHOSA) has a Research & Development of kr0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Chosa Oncology AB and its competitors.
Is Chosa Oncology AB's Research & Development too high?
Chosa Oncology AB's current Research & Development is kr0.00 Mil. Overall, Chosa Oncology AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Chosa Oncology AB's Research & Development compare to VRTX and REGN?
Chosa Oncology AB's Research & Development of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Chosa Oncology AB and its competitors. Chosa Oncology AB's current Research & Development is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chosa Oncology AB stock overvalued right now?
Chosa Oncology AB (XSAT:CHOSA) has a current Research & Development of kr0.00 Mil. The current Research & Development is kr0.00 Mil. Chosa Oncology AB's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Chosa Oncology AB (XSAT:CHOSA), the current Research & Development is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chosa Oncology AB Business Description

Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Chosa Oncology AB is a biotechnology company engaged in the research and development in immunotherapy on therapeutic cancer vaccines.
31GF Score

Get the complete analysis for XSAT:CHOSA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.83
Price